165 related articles for article (PubMed ID: 12135469)
21. Lymphoma- and leukemia-associated cutaneous atypical CD30+ T-cell reactions.
Su LD; Duncan LM
J Cutan Pathol; 2000 May; 27(5):249-54. PubMed ID: 10847550
[TBL] [Abstract][Full Text] [Related]
22. Th2 cytokine mRNA expression in primary cutaneous CD30-positive lymphoproliferative disorders: successful treatment with recombinant interferon-gamma.
Yagi H; Tokura Y; Furukawa F; Takigawa M
J Invest Dermatol; 1996 Dec; 107(6):827-32. PubMed ID: 8941669
[TBL] [Abstract][Full Text] [Related]
23. Lymphomatoid papulosis type D: a newly described variant easily confused with cutaneous aggressive CD8-positive cytotoxic T-cell lymphoma.
Cardoso J; Duhra P; Thway Y; Calonje E
Am J Dermatopathol; 2012 Oct; 34(7):762-5. PubMed ID: 22688398
[TBL] [Abstract][Full Text] [Related]
24. A case of lymphomatoid papulosis type E in a young adult: An uncommon entity.
Rajashekara Swamy M; Pollock S; J Goldberg L; Shen L
J Cutan Pathol; 2021 May; 48(5):694-700. PubMed ID: 33533041
[TBL] [Abstract][Full Text] [Related]
25. [Lymphomatoid papulosis in a child].
Léauté-Labrèze C; Bioulac-Sage P; Belleannée G; Merlio JP; Vergnes P; Maleville J; Taïeb A
Arch Pediatr; 1995 Oct; 2(10):984-7. PubMed ID: 7496478
[TBL] [Abstract][Full Text] [Related]
26. CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma.
Liu HL; Hoppe RT; Kohler S; Harvell JD; Reddy S; Kim YH
J Am Acad Dermatol; 2003 Dec; 49(6):1049-58. PubMed ID: 14639383
[TBL] [Abstract][Full Text] [Related]
27. Ki-1 (CD30) expression in differentiation of lymphomatoid papulosis from arthropod bite reactions.
Smoller BR; Longacre TA; Warnke RA
Mod Pathol; 1992 Sep; 5(5):492-6. PubMed ID: 1344811
[TBL] [Abstract][Full Text] [Related]
28. CD30-Positive Lymphoproliferative Disorders.
Nikolaenko L; Zain J; Rosen ST; Querfeld C
Cancer Treat Res; 2019; 176():249-268. PubMed ID: 30596222
[TBL] [Abstract][Full Text] [Related]
29. CD30 Positive Lymphomatoid Angiocentric Drug Reactions: Characterization of a Series of 20 Cases.
Magro CM; Olson LC; Nguyen GH; de Feraudy SM
Am J Dermatopathol; 2017 Jul; 39(7):508-517. PubMed ID: 27655118
[TBL] [Abstract][Full Text] [Related]
30. Intralymphatic cutaneous anaplastic large cell lymphoma/lymphomatoid papulosis: expanding the spectrum of CD30-positive lymphoproliferative disorders.
Samols MA; Su A; Ra S; Cappel MA; Louissant A; Knudson RA; Ketterling RP; Said J; Binder S; Harris NL; Feldman AL; Kim J; Kim YH; Gratzinger D
Am J Surg Pathol; 2014 Sep; 38(9):1203-11. PubMed ID: 24805854
[TBL] [Abstract][Full Text] [Related]
31. Epstein-Barr Virus-Associated Lymphomatoid Papules: A Sign of Immunosuppression Resembling Lymphomatoid Papulosis.
Hooper MJ; Lee WJ; LeWitt TM; Nguyen C; Griffin T; Chung C; Zhou XA; Guitart J
Am J Dermatopathol; 2023 Dec; 45(12):789-800. PubMed ID: 37982462
[TBL] [Abstract][Full Text] [Related]
32. [Lymphomatoid papulosis].
Dreno B
Presse Med; 1995 Jun; 24(23):1084-7. PubMed ID: 7567810
[TBL] [Abstract][Full Text] [Related]
33. Expression of chemokines and chemokine receptors in cutaneous CD30+ lymphoproliferative disorders.
Yamaguchi T; Ohshima K; Karube K; Kawano R; Nakayama J; Suzumiya J; Kikuchi M
Br J Dermatol; 2006 May; 154(5):904-9. PubMed ID: 16634894
[TBL] [Abstract][Full Text] [Related]
34. Lack of c-kit (CD117) expression in CD30+ lymphomas and lymphomatoid papulosis.
Rassidakis GZ; Georgakis GV; Oyarzo M; Younes A; Medeiros LJ
Mod Pathol; 2004 Aug; 17(8):946-53. PubMed ID: 15105813
[TBL] [Abstract][Full Text] [Related]
35. Death receptor apoptosis signaling mediated by FADD in CD30-positive lymphoproliferative disorders involving the skin.
Clarke LE; Bayerl MG; Bruggeman RD; Mauger D; Ioffreda MD; Abou-Elella A; Helm KF
Am J Surg Pathol; 2005 Apr; 29(4):452-9. PubMed ID: 15767797
[TBL] [Abstract][Full Text] [Related]
36. Lymphomatoid papulosis: a clinical case.
Sass U; Shahabpour M; André J; Ledoux M
Dermatology; 1995; 190(4):327-9. PubMed ID: 7655118
[TBL] [Abstract][Full Text] [Related]
37. Primary cutaneous CD30 positive T-cell lymphoproliferative disorders with aberrant expression of PAX5: report of three cases.
Hagiwara M; Tomita A; Takata K; Shimoyama Y; Yoshino T; Tomita Y; Nakamura S
Pathol Int; 2012 Apr; 62(4):264-70. PubMed ID: 22449230
[TBL] [Abstract][Full Text] [Related]
38. CD30 role in the progression of epithelial tumors?
Fernandez-Flores A
Am J Dermatopathol; 2010 May; 32(3):315. PubMed ID: 20182340
[No Abstract] [Full Text] [Related]
39. Expression of CD30 antigen in superficial mycotic infections of the skin: a possible non-specific finding without clinical relevance.
Müller CS; Schmaltz R; Vogt T; Pföhler C
Mycoses; 2011 Sep; 54(5):e360-3. PubMed ID: 20557465
[TBL] [Abstract][Full Text] [Related]
40. CD30/Ki-1-positive lymphoproliferative disorders of the skin--clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group.
Paulli M; Berti E; Rosso R; Boveri E; Kindl S; Klersy C; Lazzarino M; Borroni G; Menestrina F; Santucci M
J Clin Oncol; 1995 Jun; 13(6):1343-54. PubMed ID: 7751878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
